Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02839668 | The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)(TIVA/TCI-BC) | completed | Phase 2 | 120 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY |
| 16 |
| Oct 28, 2019 |
| clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT04112836 | Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer(PAC-MAIN) | unknown | — | 186 | Moscow Clinical Scientific CenterOTHER | 6 | Oct 16, 2019 | clinicaltrials |
| NCT02941601 | A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 27, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | completed | Phase 3 | 1,072 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 25, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT01025284 | A Study for Participants With Small-Cell Lung Cancer | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00191126 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | completed | Phase 3 | 263 | Eli Lilly and CompanyINDUSTRY | 15 | Sep 12, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT01901146 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer(Lilac) | completed | Phase 3 | 725 | AmgenINDUSTRY | 18 | Aug 7, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT01525550 | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 4 | 106 | PfizerINDUSTRY | 15 | Jul 30, 2019 | clinicaltrials |
| NCT02238366 | Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer(CHRONOS3) | completed | — | 368 | IpsenINDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT02500641 | Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout(FORWARD) | completed | Phase 4 | 196 | Menarini International Operations Luxembourg SAINDUSTRY | 6 | Jun 21, 2019 | clinicaltrials |
| NCT01935154 | Efficacy Study of Vx001 Vaccine in NSCLC Patients | completed | Phase 2 | 221 | Vaxon BiotechINDUSTRY | 8 | Jun 19, 2019 | clinicaltrials |
| NCT01367665 | STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | completed | Phase 2 | 1,232 | Hoffmann-La RocheINDUSTRY | 37 | Jun 6, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT02467907 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | completed | Phase 2 | 152 | Hoffmann-La RocheINDUSTRY | 18 | Jun 3, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT03109158 | NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 1 | NanoCarrier Co., Ltd.INDUSTRY | 4 | Apr 29, 2019 | clinicaltrials |
| NCT03042442 | Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy(CDNPAN) | completed | — | 114 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | completed | Phase 3 | 719 | PfizerINDUSTRY | 27 | Feb 7, 2019 | clinicaltrials |
| NCT01020448 | Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer(Triptocare) | completed | Phase 3 | 339 | IpsenINDUSTRY | 10 | Jan 30, 2019 | clinicaltrials |
| NCT03811431 | Contrast Enhanced Ultrasound Guidance Biopsy for the Diagnosis of Liver Tumors(ConCLUDe) | unknown | N/A | 138 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT00828386 | Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers(NPC2006) | terminated | Phase 3 | 83 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 4 | Jan 18, 2019 | clinicaltrials |
| NCT01383863 | A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer(TRIPTOCARE LT) | completed | — | 180 | IpsenINDUSTRY | 7 | Jan 14, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 | clinicaltrials |
| NCT02633800 | Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) | terminated | Phase 2 | 87 | Daiichi SankyoINDUSTRY | 7 | Jan 7, 2019 | clinicaltrials |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | completed | Phase 2 | 219 | Janssen Research & Development, LLCINDUSTRY | 14 | Jan 4, 2019 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT00789633 | Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | completed | Phase 3 | 353 | AB ScienceINDUSTRY | 5 | Dec 17, 2018 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials